Aridis Pharmaceuticals Inc. (ARDS)
| Market Cap | 33.59M |
| Revenue (ttm) | 548,000 |
| Net Income (ttm) | -43.33M |
| Shares Out | 14.05M |
| EPS (ttm) | -3.95 |
| PE Ratio | n/a |
| Forward PE | 11.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,063 |
| Open | 2.51 |
| Previous Close | 2.31 |
| Day's Range | 2.27 - 2.49 |
| 52-Week Range | 2.31 - 8.47 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 15.00 (+527.6%) |
| Earnings Date | Nov 19, 2021 |
About ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginos...
Financial Performance
In 2020, ARDS's revenue was $1,000,000, a decrease of -2.15% compared to the previous year's $1.02 million. Losses were -$22.33 million, -24.76% less than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 15.00, which is an increase of 527.62% from the latest price.
News
New Strong Sell Stocks for November 15th
ARDS, CNNE, EXK, GP, and IFF have been added to the Zacks Rank #5 (Strong Sell) List on November 15, 2021.
Aridis Pharmaceuticals Announces Third Quarter 2021 Results
LOS GATOS, Calif., Nov. 10, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
ARIDIS PHARMACT (ARDS) Reports Q2 Loss, Misses Revenue Estimates
ARIDIS PHARMACT (ARDS) delivered earnings and revenue surprises of 3.51% and -91.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aridis Pharmaceuticals Announces Second Quarter 2021 Results
LOS GATOS, Calif., Aug. 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for
ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market
LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immuno...
LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZe...
LOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/ST...
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL). Binding analyse...
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength?
ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stren...
Aridis Pharmaceuticals Announces First Quarter 2021 Results
LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
CORRECTING and REPLACING Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the M...
PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for t...
PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update
LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...
Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...
Aridis, Kermode Enter In Licensing And Discovery Agreement For Zoonotic Viruses
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an out-licensing and product discovery agreement with a privately-held Kermode Biotechnologies Inc. Kermode works on vaccines and mAbs for zoon...
Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company sa...
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutr...
LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mA...
SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting ...
SAN JOSE, Calif., Oct. 19, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective ...